Ypsomed Holding (SWX:YPSN) - Aandelenkoers, Nieuws & Analyse

YPSN Overzicht aandelen

Ypsomed Holding AG ontwikkelt, produceert en verkoopt samen met haar dochterondernemingen injectie- en infusiesystemen voor farmaceutische en biotechnologische bedrijven.

Over het bedrijf

YPSN fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	4/6
Prestaties in het verleden	5/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 23.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 33.3% per jaar groeien

De winst groeide het afgelopen jaar met 52.8%

Risicoanalyse

Geen risico's gedetecteerd voor YPSN uit onze risicocontroles.

Ypsomed Holding AG Concurrenten

Alcon

SWX:ALC

CHF 39.4b

IVF Hartmann Holding

SWX:VBSN

CHF 343.0m

COLTENE Holding

SWX:CLTN

CHF 329.8m

Medacta Group

SWX:MOVE

CHF 2.2b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Ypsomed Holding
Historische aandelenkoersen
Huidige aandelenkoers	CHF 409.50
52 Week Hoogtepunt	CHF 439.00
52 Week Laag	CHF 255.50
Bèta	0.97
11 maand verandering	-0.73%
3 maanden verandering	3.80%
1 Jaar Verandering	56.60%
33 jaar verandering	131.09%
5 jaar verandering	215.49%
Verandering sinds IPO	453.38%

Recent nieuws en updates

Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects

Aug 13

Recent updates

Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects

Aug 13

There Are Reasons To Feel Uneasy About Ypsomed Holding's (VTX:YPSN) Returns On Capital

Jul 31

If EPS Growth Is Important To You, Ypsomed Holding (VTX:YPSN) Presents An Opportunity

Jul 03

Here's Why Ypsomed Holding AG's (VTX:YPSN) CEO May Deserve A Raise

Jun 19

Should You Investigate Ypsomed Holding AG (VTX:YPSN) At CHF395?

Jun 10

Here's What Analysts Are Forecasting For Ypsomed Holding AG (VTX:YPSN) After Its Full-Year Results

May 25

Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects

May 08

Investors Could Be Concerned With Ypsomed Holding's (VTX:YPSN) Returns On Capital

Apr 07

Is There Now An Opportunity In Ypsomed Holding AG (VTX:YPSN)?

Mar 09

Here's Why We Think Ypsomed Holding (VTX:YPSN) Might Deserve Your Attention Today

Feb 07

These 4 Measures Indicate That Ypsomed Holding (VTX:YPSN) Is Using Debt Reasonably Well

Jan 17

Is Now The Time To Put Ypsomed Holding (VTX:YPSN) On Your Watchlist?

Dec 27

Investors Shouldn't Be Too Comfortable With Ypsomed Holding's (VTX:YPSN) Robust Earnings

Nov 24

What Is Ypsomed Holding AG's (VTX:YPSN) Share Price Doing?

Oct 19

Why Ypsomed Holding AG (VTX:YPSN) Could Be Worth Watching

Jul 14

Here's What's Concerning About Ypsomed Holding's (VTX:YPSN) Returns On Capital

Jun 20

Should You Investigate Ypsomed Holding AG (VTX:YPSN) At CHF161?

Feb 28

Rendement voor aandeelhouders

	YPSN	CH Medical Equipment	CH Markt
7D	6.0%	-0.7%	-1.0%
1Y	56.6%	19.4%	10.1%

Rendement versus industrie: YPSN overtrof de Swiss Medical Equipment industrie, die het afgelopen jaar een rendement 19.4 % opleverde.

Rendement versus markt: YPSN overtrof de Swiss markt, die het afgelopen jaar een rendement opleverde van 10.1 %.

Prijsvolatiliteit

Is YPSN's price volatile compared to industry and market?
YPSN volatility
YPSN Average Weekly Movement	4.0%
Medical Equipment Industry Average Movement	3.8%
Market Average Movement	3.2%
10% most volatile stocks in CH Market	7.0%
10% least volatile stocks in CH Market	1.6%

Stabiele aandelenkoers: YPSN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van YPSN is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1984	2,296	Simon Michel	www.ypsomed.com

Ypsomed Holding AG ontwikkelt, produceert en verkoopt samen met haar dochterondernemingen injectie- en infusiesystemen voor farmaceutische en biotechnologische bedrijven. Het bedrijf opereert via twee segmenten, Ypsomed Delivery Systems en Ypsomed Diabetes Care. Het segment Ypsomed Delivery Systems levert verschillende injectiesystemen, zoals peninjectoren, auto-injectoren en draagbare injectoren, evenals andere slimme apparaten.

Ypsomed Holding AG Samenvatting

Hoe verhouden de winst en inkomsten van Ypsomed Holding zich tot de beurswaarde?
YPSN fundamentele statistieken
Marktkapitalisatie	CHF 5.59b
Inkomsten(TTM)	CHF 78.37m
Inkomsten(TTM)	CHF 548.46m

71.3x

Koers/Winstverhouding

10.2x

P/S-verhouding

Is YPSN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
YPSN resultatenrekening (TTM)
Inkomsten	CHF 548.46m
Kosten van inkomsten	CHF 359.40m
Brutowinst	CHF 189.05m
Overige uitgaven	CHF 110.69m
Inkomsten	CHF 78.37m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

Nov 13, 2024

Winst per aandeel (EPS)	5.74
Brutomarge	34.47%
Nettowinstmarge	14.29%
Schuld/Eigen Vermogen Verhouding	41.4%

Hoe presteerde YPSN op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.5%

Huidig dividendrendement

35%

Uitbetalingsratio

YPSN Overzicht aandelen

Beloningen

Risicoanalyse

Ypsomed Holding AG Concurrenten

SWX:ALC

CHF 39.4b

SWX:VBSN

CHF 343.0m

SWX:CLTN

CHF 329.8m

SWX:MOVE

CHF 2.2b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Now 23% undervalued

Now 21% undervalued

Ypsomed Holding AG to Report First Half, 2025 Results on Nov 13, 2024

Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects

MTD Medical Technology and Devices S.A. completed the acquisition of the Pen Needle and Blood Glucose Monitoring Businesses of Ypsomed Holding AG (SWX:YPSN).

MTD Medical Technology and Devices S.A. completed the acquisition of the Pen Needle and Blood Glucose Monitoring Businesses of Ypsomed Holding AG (SWX:YPSN).

Recent updates

Now 23% undervalued

Now 21% undervalued

Ypsomed Holding AG to Report First Half, 2025 Results on Nov 13, 2024

Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects

MTD Medical Technology and Devices S.A. completed the acquisition of the Pen Needle and Blood Glucose Monitoring Businesses of Ypsomed Holding AG (SWX:YPSN).

MTD Medical Technology and Devices S.A. completed the acquisition of the Pen Needle and Blood Glucose Monitoring Businesses of Ypsomed Holding AG (SWX:YPSN).

There Are Reasons To Feel Uneasy About Ypsomed Holding's (VTX:YPSN) Returns On Capital

If EPS Growth Is Important To You, Ypsomed Holding (VTX:YPSN) Presents An Opportunity

Price target increased by 7.6% to CHF378

Here's Why Ypsomed Holding AG's (VTX:YPSN) CEO May Deserve A Raise

Should You Investigate Ypsomed Holding AG (VTX:YPSN) At CHF395?

Here's What Analysts Are Forecasting For Ypsomed Holding AG (VTX:YPSN) After Its Full-Year Results

Full year 2024 earnings released: EPS: CHF5.74 (vs CHF3.82 in FY 2023)

Investor sentiment improves as stock rises 17%

Ypsomed Holding AG to Report Q4, 2024 Results on May 22, 2024

Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects

Price target increased by 14% to CHF365

Investors Could Be Concerned With Ypsomed Holding's (VTX:YPSN) Returns On Capital

Is There Now An Opportunity In Ypsomed Holding AG (VTX:YPSN)?

Here's Why We Think Ypsomed Holding (VTX:YPSN) Might Deserve Your Attention Today

We Think Ypsomed Holding (VTX:YPSN) Can Stay On Top Of Its Debt

Ypsomed Holding AG's (VTX:YPSN) Popularity With Investors Is Clear

Here's What's Concerning About Ypsomed Holding's (VTX:YPSN) Returns On Capital

Should You Investigate Ypsomed Holding AG (VTX:YPSN) At CHF298?

First half 2024 earnings released: EPS: CHF2.68 (vs CHF1.17 in 1H 2023)

Do Ypsomed Holding's (VTX:YPSN) Earnings Warrant Your Attention?

Price target increased by 14% to CHF315

Ypsomed Holding AG to Report First Half, 2024 Results on Nov 15, 2023

Ypsomed Holding (VTX:YPSN) Seems To Use Debt Quite Sensibly

Ypsomed Holding (VTX:YPSN) May Have Issues Allocating Its Capital

Should You Think About Buying Ypsomed Holding AG (VTX:YPSN) Now?

Ypsomed Holding AG, Annual General Meeting, Jun 26, 2024

Upcoming dividend of €1.30 per share at 0.5% yield

Should You Be Adding Ypsomed Holding (VTX:YPSN) To Your Watchlist Today?

Consensus EPS estimates increase by 15%

Ypsomed Holding (VTX:YPSN) Seems To Use Debt Quite Sensibly

Price target increased by 13% to CHF257

Ypsomed Holding AG to Report Fiscal Year 2023 Results on May 24, 2023

What Does Ypsomed Holding AG's (VTX:YPSN) Share Price Indicate?

Ypsomed Holding (VTX:YPSN) Could Be Struggling To Allocate Capital

Ypsomed Holding AG, Annual General Meeting, Jun 28, 2023

At CHF187, Is It Time To Put Ypsomed Holding AG (VTX:YPSN) On Your Watch List?

These 4 Measures Indicate That Ypsomed Holding (VTX:YPSN) Is Using Debt Reasonably Well

Price target increased to CHF223

Mediq B.V. completed the acquisition of DiaExpert GmbH from Ypsomed Holding AG (SWX:YPSN).

Is Now The Time To Put Ypsomed Holding (VTX:YPSN) On Your Watchlist?

Investor sentiment deteriorated over the past week

Now 21% undervalued

Investors Shouldn't Be Too Comfortable With Ypsomed Holding's (VTX:YPSN) Robust Earnings

Consensus forecasts updated

Price target increased to CHF207

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

No independent directors

What Is Ypsomed Holding AG's (VTX:YPSN) Share Price Doing?

Price target decreased to CHF192

Why Ypsomed Holding AG (VTX:YPSN) Could Be Worth Watching

Upcoming dividend of CHF0.60 per share

Here's What's Concerning About Ypsomed Holding's (VTX:YPSN) Returns On Capital

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat